Advertisement

Topics

Checkmate Pharmaceuticals Presents Clinical Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting

09:30 EDT 17 Apr 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
CMP-001 - pembrolizumab combination reverses resistance to PD-1 inhibition in patients with advanced melanoma who had progressed on prior anti-PD-1 therapy CMP-001 shows deep and durable clinical responses in both injec...

Other Sources for this Article

Company Contact:
Checkmate Pharmaceuticals, Inc.
Art Krieg, MD, CEO
akrieg@checkmatepharma.com
or
Media Contact:
MacDougall Biomedical Communications
Karen Sharma, 781-235-3060
ksharma@macbiocom.com

NEXT ARTICLE

More From BioPortfolio on "Checkmate Pharmaceuticals Presents Clinical Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...

Melanoma
Melanoma is a highly malignant tumor of melanin-forming cells (melanocytes) There are most commonly found in the skin (resulting from sunlight exposure), but also in the eyes and mucous membranes. Metastasis to other regions of the body is also common....

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...